$2655 | Single User
$5295 | Global License

NPS+ Renal Cell Carcinoma (US) 2018
[Report Updated: 01-02-2018]

Published by FirstWord Pharma: 01 Feb 2018 | 197068 | In Stock
Related Topics: Novartis , Pfizer , Roche

Introduction



Why are some US RCC brands standing out more than others?

There are various options available to US oncologists to treat renal cell carcinoma (RCC). Clearly some of these options are achieving greater levels of loyalty and satisfaction than others – but why? What are the key factors driving physician choice and how does each of the leading brands compare to its competitors?

NPS+ RCC (US) gives a unique insight into the overall brand health of 10 leading treatments for RCC currently being used in North America. 100 oncologists were surveyed on key issues including brand messaging, prescribing behaviour and satisfaction levels. The results provide valuable insight for brand marketers seeking new ways to stand out.

Request sample pages



Top Takeaways

One brand leads the way, and the rest don’t even get close. Of the 10 brands included in the survey, one brand is just under 20 points ahead of second place, and 7/10 brands don’t even achieve a positive NPS. Which one leads the way, and where are the key fights for lower places?

Loyalty is proving difficult to achieve. Loyalty scores of 4 or more are what brands are aiming for, but for RCC treatments, even the highest scores are not even close in this latest survey. Is clinical differentiation really that low?

Despite low loyalty, satisfaction is high. Why are oncologists so happy with the numerous drugs on offer? And is there any more that could be done to improve satisfaction scores even more?

Marketing messaging could be the key. Which brands are associated with key issues such as safety, efficacy, convenient administration and cost effectiveness? Could more be done to promote key benefits?

In their own words. What do doctors say each brand means to them? For example, which brand is described as ‘one of the most effective agents for RCC’ and which brand is ‘no longer useful’?

Insight into 10 RCC Treatments

Afinitor (everolimus; Novartis)

Avastin (bevacizumab; Roche)

Cabometyx (cabozantinib; Exelixis)

Inlyta (axitinib; Pfizer)

Lenvima (lenvatinib; Eisai/Novartis)

Nexavar (sorafenib; Bayer/Amgen)

Opdivo (nivolumab; Bristol-Myers Squibb)

Sutent (sunitinib; Pfizer)

Torisel (temsirolimus; Pfizer)

Votrient (pazopanib; Novartis)

Explore Important Brand Loyalty Issues

NPS+ RCC US offers valuable insight into brand loyalty from the perspective of those currently prescribing treatments for RCC to patients. You’ll discover:

Exactly how satisfied the US market is.

How loyal doctors are to your brand.

How many other brands your Promoters recommend.

Which other brands your Promoters and Detractors recommend.

How much market share your brand has among Promoters and Detractors.

How much market share you stand to gain by converting Detractors into Promoters.

Which messages Promoters, Passives and Detractors associate with your brand.

Your brand DNA: what doctors really think of your brand—in their own words.

A Report Based on Expert Knowledge

We surveyed 100 US-based oncologists chosen from the largest community of validated physicians in the world. We conducted the survey between January 10-20, 2018.

What is Net Promoter® Score?

NPS is a customer loyalty metric developed by (and a registered trademark of) Fred Reichheld, Bain & Company, and Satmetrix. It was introduced by Reichheld in his 2003 Harvard Business Review article One Number You Need to Grow.

How does NPS work?

NPS measures overall brand satisfaction and loyalty by asking one simple question:

"How likely are you to recommend this brand to a colleague?"

Responses - given on a scale of 0 (not at all likely) to 10 (extremely likely)—are used to classify respondents into 3 categories:

Detractors are those who answer 0 – 6.

Passives are those who answer 7 – 8.

Promoters are those who answer 9 - 10.

How is NPS calculated?

The percentage of detractors - the percentage of promoters = NPS.

For example, 25% Promoters, 55% Passives and 20% Detractors give you an NPS of +5.

NPS can range from -100 (everybody is a Detractor) to +100 (everybody is a Promoter). The higher the score the healthier the brand.

What is FirstView NPS+?

NPS+ turns your Net Promoter Score into actionable information by answering key questions about brand loyalty.

Each NPS+ report examines doctors’ relationships with the brands used to treat a major disease area—measuring brand loyalty and showing you how it affects your market share. NPS+ also examines “brand DNA”, revealing in doctors’ own words what brands mean to them.

Instead of one simple metric, NPS+ gives you a detailed picture of brand health that highlights areas for improvement, and helps you see exactly what steps you need to take next.

MONEY BACK GUARANTEE!

At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.

About FirstWord

FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.

FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.

FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.

FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.

Learn more at www.firstwordgroup.com.

Table of Contents
for NPS+ Renal Cell Carcinoma (US) 2018 [Report Updated: 01-02-2018]

  • 1.Chart 1: Net Promoter Score?

    2.Chart 2: How loyal are doctors to my brand?

    3.Chart 3: How satisfied is the market?

    4.Chart 4: How many other brands are promoted by my Promoters?

    5.Chart 5: Which other brand is most promoted by my Promoters?

    6.Chart 6: Which other brands are promoted by my Detractors?

    7.Chart 7: What is my brand's market share among Promoters and Detractors?

    8.Chart 8: What brand messages are associated with Promoters, Passives and Detractors (by

    brand)?

    9.Chart 9: What does my brand represent to Promoters and Detractors (by brand)?

    Appendix

Additional Details

Publisher

FirstWord Pharma

Publisher Information

Reference

197068 |

Report Format

PDF

FirstWord Pharma Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Head and Neck Squamous Cell Carcinoma: KOL Insight
IntroductionImmunotherapies are about to transform HNSCC treatment. Can one brand corner the market?...
01 Mar 2016 by FirstWord Pharma USD $7,900 More Info
NPS+ Renal Cell Carcinoma (US)
IntroductionTwo brands lead the RCC treatment market. How does your brand stack up?US oncologists ma...
01 Feb 2016 by FirstWord Pharma USD $2,495 More Info
NPS+ Renal Cell Carcinoma (EU5)
IntroductionCompare 8 major RCC brands. Learn which one scores 6 times higher than any other?FirstVi...
01 Feb 2016 by FirstWord Pharma USD $2,495 More Info
Non-Small Cell Lung Cancer: Update Bulletin [Jan 2016]
IntroductionGain new KOL insights on the latest events that have the potential to shape the targeted...
01 Jan 2016 by FirstWord Pharma USD $995 More Info
Non-Small Cell Lung Cancer: KOL Insight
IntroductionNon-Small Cell Lung Cancer: KOL Insight offers detailed expert opinion on the continuing...
01 Jul 2015 by FirstWord Pharma USD $7,900 More Info
Physician Views – Taking a post-ASCO pulse on the PD-L1 biomarker debate in non-small-cell lung cancer
ScopeThe data presented at this year's ASCO annual meeting, which has subsequently fuelled the most ...
01 Jun 2015 by FirstWord Pharma USD $695 More Info
Physician Views: Oncologist expectations for immunotherapy in first-line non-small-cell lung cancer
ScopeMuch of the debate around cancer immunotherapy at the recent ASCO annual meeting focused on the...
01 Jun 2015 by FirstWord Pharma USD $695 More Info
Physician Views: Will an Opdivo/Yervoy combination succeed in melanoma and can Keytruda keep pace in non-small-cell lung cancer?
Scope New data presented at the annual meeting of the American Association for Cancer Research (AACR...
23 Apr 2015 by FirstWord Pharma USD $695 More Info
Renal Cell Carcinoma: KOL Insight
IntroductionWill new checkpoint inhibitors revive immunotherapy in RCC?Renal Cell Carcinoma: KOL Ins...
01 Feb 2015 by FirstWord Pharma USD $7,900 More Info
Physician Views: Reaction to Bristol-Myers Squibb's Opdivo data in non-small-cell lung cancer
Scope Studies of Bristol-Myers Squibb's PD-1 inhibitor nivolumab in non-small-cell lung cancer (NSCL...
06 Nov 2014 by FirstWord Pharma USD $695 More Info

This report is published by FirstWord Pharma

Download Free Report Summary PDF

NPS+ Renal Cell Carcinoma (US) 2018 [Report Updated: 01-02-2018] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...

  • 360i Research
  • 99Strategy
  • Allied Market Research
  • Asia Market Information & Development Co.
  • Azoth Analytics
  • BioInformant
  • Black Swan Analysis
  • Canadean
  • CBR Pharma Insights
  • CRI
  • Current Analysis
  • Current Partnering
  • Daedal Research
  • Data bridge
  • Delve Insight
  • DPI Research
  • FirstWord Pharma
  • Future Market Insights
  • GBI Research
  • Global Data
  • Global Markets Direct
  • Global Research and Data Services GRDS
  • GMR Data
  • HeyReport
  • HongChun
  • HTStec
  • ICD Research
  • iGATE Research
  • IMARC
  • Industry ARC
  • Inkwood Research
  • IQ4I
  • Jain PharmaBiotech
  • Kelly Scientific
  • La Merie
  • Lifescience Intellipedia
  • LP Information
  • Market Data Forecast
  • Market Research Future
  • Marketline
  • MarketsandMarkets
  • McDerson
  • MedMarket Diligence
  • Meticulous Research
  • MicroMarketMonitor
  • MIReports
  • Mordor Intelligence LLC
  • MP Advisors
  • Occams Business Research
  • Prof Research
  • Progressive Markets
  • ProGrow Pharma Partners
  • Renub
  • Research Impact
  • RNCOS
  • Rockville Research
  • S&P Consulting
  • StratisticsMRC
  • The Business Research Company
  • Triton Market Research
  • Venture Planning Group (VPG)